Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
Identifieur interne : 000F15 ( Main/Corpus ); précédent : 000F14; suivant : 000F16Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
Auteurs : Sudhir Mehta ; Sudhir Bhandari ; Shaurya MehtaSource :
- Journal of global antimicrobial resistance [ 2213-7173 ] ; 2020.
English descriptors
- KwdEn :
- Antiviral Agents (administration & dosage), Betacoronavirus (isolation & purification), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (prevention & control), Coronavirus Infections (virology), Health Personnel (MeSH), Humans (MeSH), Hydroxychloroquine (administration & dosage), India (MeSH), Pandemics (prevention & control), Pneumonia, Viral (prevention & control), Pneumonia, Viral (virology), Pre-Exposure Prophylaxis (methods), SARS-CoV-2 (MeSH).
- MESH :
- chemical , administration & dosage : Antiviral Agents, Hydroxychloroquine.
- geographic : India.
- drug therapy : Coronavirus Infections.
- isolation & purification : Betacoronavirus.
- methods : Pre-Exposure Prophylaxis.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Health Personnel, Humans, SARS-CoV-2.
Abstract
The potentiality of Hydroxychloroquine (HCQ) for pre-exposure prophylaxis against SARS-CoV-2 has not been explored in randomized controlled trials. However, there is rationale behind this potentiality in terms of demonstrated in-vitro effect of HCQ against SARS-CoV-2, safety profile of HCQ in healthy individuals and a recent observational study demonstrating benefits of HCQ prophylaxis in terms of a significant reduction (>80%) in the odds of SARS-CoV-2 infection in the health-care workers (HCWs) with the intake of six or more doses of HCQ prophylaxis as per the guidelines of the National Task Force for COVID-19 in India. Hence, pre-exposure prophylaxis with HCQ in appears to be a reasonable strategy in the current scenario for prevention of SARS-CoV-2 infection in healthy HCWs.
DOI: 10.1016/j.jgar.2020.07.022
PubMed: 32777441
PubMed Central: PMC7836824
Links to Exploration step
pubmed:32777441Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?</title><author><name sortKey="Mehta, Sudhir" sort="Mehta, Sudhir" uniqKey="Mehta S" first="Sudhir" last="Mehta">Sudhir Mehta</name><affiliation><nlm:affiliation>Department of Medicine, SMS Medical College, Jaipur, India. Electronic address: s.smehta@hotmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Bhandari, Sudhir" sort="Bhandari, Sudhir" uniqKey="Bhandari S" first="Sudhir" last="Bhandari">Sudhir Bhandari</name><affiliation><nlm:affiliation>Department of Medicine, SMS Medical College, Jaipur, India.</nlm:affiliation></affiliation></author><author><name sortKey="Mehta, Shaurya" sort="Mehta, Shaurya" uniqKey="Mehta S" first="Shaurya" last="Mehta">Shaurya Mehta</name><affiliation><nlm:affiliation>Jaslok Hospital & Research Centre, Mumbai, India.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32777441</idno><idno type="pmid">32777441</idno><idno type="doi">10.1016/j.jgar.2020.07.022</idno><idno type="pmc">PMC7836824</idno><idno type="wicri:Area/Main/Corpus">000F15</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F15</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?</title><author><name sortKey="Mehta, Sudhir" sort="Mehta, Sudhir" uniqKey="Mehta S" first="Sudhir" last="Mehta">Sudhir Mehta</name><affiliation><nlm:affiliation>Department of Medicine, SMS Medical College, Jaipur, India. Electronic address: s.smehta@hotmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Bhandari, Sudhir" sort="Bhandari, Sudhir" uniqKey="Bhandari S" first="Sudhir" last="Bhandari">Sudhir Bhandari</name><affiliation><nlm:affiliation>Department of Medicine, SMS Medical College, Jaipur, India.</nlm:affiliation></affiliation></author><author><name sortKey="Mehta, Shaurya" sort="Mehta, Shaurya" uniqKey="Mehta S" first="Shaurya" last="Mehta">Shaurya Mehta</name><affiliation><nlm:affiliation>Jaslok Hospital & Research Centre, Mumbai, India.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of global antimicrobial resistance</title><idno type="eISSN">2213-7173</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (administration & dosage)</term><term>Betacoronavirus (isolation & purification)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (virology)</term><term>Health Personnel (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>India (MeSH)</term><term>Pandemics (prevention & control)</term><term>Pneumonia, Viral (prevention & control)</term><term>Pneumonia, Viral (virology)</term><term>Pre-Exposure Prophylaxis (methods)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>India</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Pre-Exposure Prophylaxis</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Health Personnel</term><term>Humans</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The potentiality of Hydroxychloroquine (HCQ) for pre-exposure prophylaxis against SARS-CoV-2 has not been explored in randomized controlled trials. However, there is rationale behind this potentiality in terms of demonstrated in-vitro effect of HCQ against SARS-CoV-2, safety profile of HCQ in healthy individuals and a recent observational study demonstrating benefits of HCQ prophylaxis in terms of a significant reduction (>80%) in the odds of SARS-CoV-2 infection in the health-care workers (HCWs) with the intake of six or more doses of HCQ prophylaxis as per the guidelines of the National Task Force for COVID-19 in India. Hence, pre-exposure prophylaxis with HCQ in appears to be a reasonable strategy in the current scenario for prevention of SARS-CoV-2 infection in healthy HCWs.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32777441</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-7173</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><PubDate><Year>2020</Year><Month>09</Month></PubDate></JournalIssue><Title>Journal of global antimicrobial resistance</Title><ISOAbbreviation>J Glob Antimicrob Resist</ISOAbbreviation></Journal><ArticleTitle>Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?</ArticleTitle><Pagination><MedlinePgn>864-865</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S2213-7165(20)30194-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jgar.2020.07.022</ELocationID><Abstract><AbstractText>The potentiality of Hydroxychloroquine (HCQ) for pre-exposure prophylaxis against SARS-CoV-2 has not been explored in randomized controlled trials. However, there is rationale behind this potentiality in terms of demonstrated in-vitro effect of HCQ against SARS-CoV-2, safety profile of HCQ in healthy individuals and a recent observational study demonstrating benefits of HCQ prophylaxis in terms of a significant reduction (>80%) in the odds of SARS-CoV-2 infection in the health-care workers (HCWs) with the intake of six or more doses of HCQ prophylaxis as per the guidelines of the National Task Force for COVID-19 in India. Hence, pre-exposure prophylaxis with HCQ in appears to be a reasonable strategy in the current scenario for prevention of SARS-CoV-2 infection in healthy HCWs.</AbstractText><CopyrightInformation>Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Sudhir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, SMS Medical College, Jaipur, India. Electronic address: s.smehta@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhandari</LastName><ForeName>Sudhir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, SMS Medical College, Jaipur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Shaurya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Jaslok Hospital & Research Centre, Mumbai, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Glob Antimicrob Resist</MedlineTA><NlmUniqueID>101622459</NlmUniqueID><ISSNLinking>2213-7165</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="N">Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065129" MajorTopicYN="N">Pre-Exposure Prophylaxis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>07</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32777441</ArticleId><ArticleId IdType="pii">S2213-7165(20)30194-6</ArticleId><ArticleId IdType="doi">10.1016/j.jgar.2020.07.022</ArticleId><ArticleId IdType="pmc">PMC7836824</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation><ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):517-525</Citation><ArticleIdList><ArticleId IdType="pubmed">32492293</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2018 Nov 7;16(1):200</Citation><ArticleIdList><ArticleId IdType="pubmed">30400791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 22;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32450107</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian J Med Res. 2020 May;151(5):459-467</Citation><ArticleIdList><ArticleId IdType="pubmed">32611916</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation><ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000F15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32777441
|texte= Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32777441" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |